Incyte - INCY Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued 1 year price targets for Incyte's stock. Their INCY share price forecasts range from $63.00 to $108.00. On average, they anticipate the company's share price to reach $84.92 in the next twelve months. This suggests a possible upside of 27.8% from the stock's current price.
View analysts price targets for INCY or view top-rated stocks among Wall Street analysts.

Incyte's stock was trading at $73.40 at the start of the year. Since then, INCY shares have decreased by 9.5% and is now trading at $66.44.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our INCY earnings forecast.

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, August, 2nd. The biopharmaceutical company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.61 by $0.24. The biopharmaceutical company had revenue of $911.40 million for the quarter, compared to the consensus estimate of $818.25 million. Incyte had a trailing twelve-month return on equity of 13.02% and a net margin of 28.46%. Incyte's quarterly revenue was up 29.1% compared to the same quarter last year. During the same period last year, the business earned $0.65 EPS.
Read the conference call transcript.

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include Dodge & Cox (9.02%), State Street Corp (4.25%), Renaissance Technologies LLC (2.31%), Price T Rowe Associates Inc. MD (1.53%), UBS Asset Management Americas Inc. (0.98%) and Northern Trust Corp (0.90%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends.

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INCY stock can currently be purchased for approximately $66.44.

Incyte (NASDAQ:INCY) has a market capitalization of $14.78 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $4.25 on an earnings per share basis.

The company employs 2,094 workers across the globe.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.